Last updated: 2026-09-29 17:03:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Merck & Co., Inc. (MRK) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $148,24, with a market capitalization of $366,84B and a P/E ratio of 115,61. Over the past 52 weeks, its price has ranged from $78,03 to $156,92. This page covers its latest market performance, valuation, price trends and company information.
$366,84B | |
$148,17 | |
$156,92 | |
$20,05 | |
$148,69 | |
2,80M | |
9,71M | |
115,61 | |
$156,92 | |
$78,03 | |
2,26% | |
-- |
Merck & Co., Inc. (MRK) is currently trading at $148,24 as of 2026-09-29 16:46:33, down 0,30% ($0,45) from the previous close of $148,69
During today's regular trading session, MRK has traded between $20,05 and $156,92, with a trading volume of 2,80M shares. The current price is near the upper end of today's range.
Over the past seven days, Merck & Co., Inc. (MRK) moved from $149,50 to $148,24, representing a decline of 0,84% ($1,26).
The stock traded between $145,60 and $153,57 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 7,88 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 89,0%
MRK is currently trading at $148,24, placing it 89,0% of the way from its 52-week low of $78,03 to its 52-week high of $156,92. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 75000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Merck & Co., Inc. (MRK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.